PT2903629T - Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino - Google Patents
Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestinoInfo
- Publication number
- PT2903629T PT2903629T PT12885969T PT12885969T PT2903629T PT 2903629 T PT2903629 T PT 2903629T PT 12885969 T PT12885969 T PT 12885969T PT 12885969 T PT12885969 T PT 12885969T PT 2903629 T PT2903629 T PT 2903629T
- Authority
- PT
- Portugal
- Prior art keywords
- inflammatory bowel
- bowel disease
- antibody conjugate
- treating inflammatory
- treating
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/058574 WO2014055073A1 (en) | 2012-10-03 | 2012-10-03 | Antigens associated with inflammatory bowel disease |
| EP12885969.1A EP2903629B1 (en) | 2012-10-03 | 2012-10-03 | Antibody conjugate for use in treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2903629T true PT2903629T (pt) | 2019-09-10 |
Family
ID=50435280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT12885969T PT2903629T (pt) | 2012-10-03 | 2012-10-03 | Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9695232B2 (OSRAM) |
| EP (1) | EP2903629B1 (OSRAM) |
| JP (1) | JP6158933B2 (OSRAM) |
| KR (1) | KR102011549B1 (OSRAM) |
| CN (2) | CN104768563B (OSRAM) |
| AU (1) | AU2012391490B2 (OSRAM) |
| CA (1) | CA2886152C (OSRAM) |
| CO (1) | CO7380754A2 (OSRAM) |
| DK (1) | DK2903629T3 (OSRAM) |
| ES (1) | ES2743423T3 (OSRAM) |
| HU (1) | HUE044927T2 (OSRAM) |
| IL (1) | IL237856B (OSRAM) |
| IN (1) | IN2015DN03229A (OSRAM) |
| MX (1) | MX364535B (OSRAM) |
| PH (1) | PH12015500662B1 (OSRAM) |
| PL (1) | PL2903629T3 (OSRAM) |
| PT (1) | PT2903629T (OSRAM) |
| RU (1) | RU2612878C2 (OSRAM) |
| SG (1) | SG11201502404WA (OSRAM) |
| SI (1) | SI2903629T1 (OSRAM) |
| WO (1) | WO2014055073A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3281952T3 (pl) | 2007-10-30 | 2020-11-16 | Philogen S.P.A. | Antygen związany z reumatoidalnym zapaleniem stawów |
| CN104768563B (zh) | 2012-10-03 | 2020-02-28 | 菲罗根股份公司 | 与炎性肠病有关的抗原 |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| US20190309060A1 (en) | 2016-01-15 | 2019-10-10 | Philogen S.P.A. | Intestinal antigens for pharmacodelivery applications |
| US11390666B2 (en) | 2017-06-07 | 2022-07-19 | Philogen S.P.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| CA3132385A1 (en) * | 2019-03-06 | 2020-09-10 | Deka Biosciences, Inc. | Il-10 variant molecules and methods of treating inflammatory disease and oncology |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| KR20230096959A (ko) | 2020-07-20 | 2023-06-30 | 데카 바이오사이언시즈, 인크. | Il-10을 포함하는 이중 시토카인 융합 단백질 |
| US20230285585A1 (en) | 2020-07-22 | 2023-09-14 | Philogen S.P.A. | Treatment of pulmonary hypertension |
| WO2023175077A1 (en) | 2022-03-17 | 2023-09-21 | Philogen S.P.A | Anti-ed-a antibodies for the treatment of pulmonary hypertension |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE425839C (de) | 1923-08-09 | 1926-03-02 | Optische Anstalt C P Goerz Akt | Verfahren zur Erzeugung des Schleifdruckes und der Schleifrelativbewegung zwischen dem Gegenstande, dessen Oberflaeche durch Schleifen bearbeitet werden soll (Glas, Linse usw.), und der Schleifflaeche des umlaufenden Schleifwerkzeuges |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| US5420012A (en) | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| EP0580859A4 (en) | 1991-03-26 | 1994-09-14 | Otsuka Pharma Co Ltd | Anti-eda monoclonal antibody |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5368854A (en) * | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| EP1137941B2 (en) | 1998-12-10 | 2013-09-11 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| CA2399866C (en) | 2000-02-24 | 2011-05-10 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| WO2001076630A1 (en) | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics and remedies for rheumatoid arthritis |
| AU5867901A (en) | 2000-05-04 | 2001-11-12 | Philogen S.R.L. | Method for detecting tumors |
| HRP20030263A2 (en) | 2000-09-07 | 2005-10-31 | Schering Aktiengesellschaft | RECEPTOR IN THE ED<SUB>b</SUB>-FIBRONECTIN-DOMAIN |
| US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| US20020187100A1 (en) | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| WO2004000216A2 (en) | 2002-06-21 | 2003-12-31 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| CN101972478B (zh) | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| WO2004094612A2 (en) | 2003-04-22 | 2004-11-04 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| WO2005086612A2 (en) | 2003-07-29 | 2005-09-22 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
| US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| JP2008514900A (ja) | 2004-07-30 | 2008-05-08 | アデザ・バイオメデイカル・コーポレイシヨン | 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法 |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| BRPI0517967B8 (pt) | 2004-11-09 | 2021-05-25 | Philogen Spa | anticorpo isolado que liga-se a tenascina-c humana |
| WO2006067633A2 (en) | 2004-12-23 | 2006-06-29 | Molmed Spa | Conjugation product |
| MX2007013875A (es) | 2005-05-11 | 2008-01-28 | Philogen Spa | Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12. |
| EP1893244A4 (en) | 2005-06-23 | 2009-06-24 | Univ Emory | AGENTS FOR IMAGING |
| WO2007005608A2 (en) * | 2005-06-30 | 2007-01-11 | Abbott Laboratories | Il-12/p40 binding proteins |
| EP2015775B1 (en) | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| EP2142567B1 (en) * | 2007-04-02 | 2013-01-16 | Philogen S.p.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| US20100183506A1 (en) * | 2007-07-25 | 2010-07-22 | Dario Neri | Antigen associated with lung cancers and lymphomas |
| PL3281952T3 (pl) | 2007-10-30 | 2020-11-16 | Philogen S.P.A. | Antygen związany z reumatoidalnym zapaleniem stawów |
| WO2010078950A2 (en) * | 2009-01-07 | 2010-07-15 | Philogen S.P.A. | Antigens associated with endometriosis, psoriatic arthritis and psoriasis |
| WO2010078945A2 (en) | 2009-01-07 | 2010-07-15 | Philogen S.P.A. | Cancer treatment |
| EP2461832B1 (en) | 2009-08-05 | 2017-06-28 | Philogen S.p.A. | Targeting of bone marrow neovasculature |
| EP2621535A1 (en) | 2010-09-29 | 2013-08-07 | Philogen S.p.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
| EP3437662B1 (en) | 2011-07-27 | 2021-02-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| CN104768563B (zh) | 2012-10-03 | 2020-02-28 | 菲罗根股份公司 | 与炎性肠病有关的抗原 |
| EP2988784A1 (en) | 2013-04-25 | 2016-03-02 | Philogen S.p.A. | Antibody-drug conjugates |
| JP2016519111A (ja) | 2013-04-26 | 2016-06-30 | フィロゲン エスピーエー | 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４ |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2012
- 2012-10-03 CN CN201280076034.8A patent/CN104768563B/zh active Active
- 2012-10-03 US US14/431,745 patent/US9695232B2/en active Active
- 2012-10-03 SG SG11201502404WA patent/SG11201502404WA/en unknown
- 2012-10-03 CA CA2886152A patent/CA2886152C/en active Active
- 2012-10-03 EP EP12885969.1A patent/EP2903629B1/en active Active
- 2012-10-03 ES ES12885969T patent/ES2743423T3/es active Active
- 2012-10-03 CN CN202010149309.2A patent/CN111329994A/zh active Pending
- 2012-10-03 RU RU2015115399A patent/RU2612878C2/ru active
- 2012-10-03 WO PCT/US2012/058574 patent/WO2014055073A1/en not_active Ceased
- 2012-10-03 SI SI201231649T patent/SI2903629T1/sl unknown
- 2012-10-03 AU AU2012391490A patent/AU2012391490B2/en active Active
- 2012-10-03 HU HUE12885969 patent/HUE044927T2/hu unknown
- 2012-10-03 DK DK12885969.1T patent/DK2903629T3/da active
- 2012-10-03 PT PT12885969T patent/PT2903629T/pt unknown
- 2012-10-03 MX MX2015003908A patent/MX364535B/es active IP Right Grant
- 2012-10-03 IN IN3229DEN2015 patent/IN2015DN03229A/en unknown
- 2012-10-03 PL PL12885969T patent/PL2903629T3/pl unknown
- 2012-10-03 KR KR1020157010676A patent/KR102011549B1/ko active Active
- 2012-10-03 JP JP2015535617A patent/JP6158933B2/ja active Active
-
2015
- 2015-03-19 IL IL23785615A patent/IL237856B/en active IP Right Grant
- 2015-03-24 PH PH12015500662A patent/PH12015500662B1/en unknown
- 2015-03-26 CO CO15069808A patent/CO7380754A2/es unknown
-
2017
- 2017-06-01 US US15/611,213 patent/US10239939B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269529A (en) | Methods for diagnosing and treating inflammatory bowel disease | |
| PT2903629T (pt) | Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino | |
| IL232167A0 (en) | Methods to improve the diagnosis of inflammatory bowel disease | |
| IL236040B (en) | Berberine for use in improving gut microbiota population | |
| HUE037823T2 (hu) | Nõi vizeletgyûjtõ eszköz | |
| IL238143A0 (en) | Antibody-drug conjugate | |
| IL222993A0 (en) | Compositions and methods for treating neoplasia, inflammatory disease and otheir disoreders | |
| IL235512B (en) | History of phenylbenzamide for use in the treatment of aquaporin-mediated diseases | |
| ZA201500457B (en) | Anti-kit antibodies and uses thereof | |
| EP2997162A4 (en) | Methods for diagnosing and treating inflammatory bowel disease | |
| ZA201408955B (en) | Anti-blys antibody | |
| EP2872036A4 (en) | IN VIVO BIOSENSOR | |
| ZA201408059B (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| IL217568A0 (en) | Multipurpose catamenial device | |
| EP2663321A4 (en) | ANTIGENIC SUBSTITUTES IN AUTOIMMUNE DISEASE | |
| ZA201409119B (en) | Polymer-nsaid conjugate | |
| IL233721A0 (en) | Soluble Manf in pancreatic beta-cell-related disorders | |
| GB201223223D0 (en) | Inflammatory bowel disease | |
| EP2543388A4 (en) | MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE | |
| SG11201500367WA (en) | In vitro assay for predicting renal proximal tubular cell toxicity | |
| EP2994486A4 (en) | USE OF ANTI-EOTAXINE ANTIBODIES FOR THE TREATMENT OF CHRONICALLY INFLAMMABLE ENDURANCE | |
| EP2723349A4 (en) | MICROARN-31 COMPOSITIONS AND METHODS OF USE IN AUTOIMMUNE DISEASES | |
| GB201206211D0 (en) | Personal urine collection apparatus | |
| GB201216947D0 (en) | Pelvic Hot Waterbottle | |
| GB201216994D0 (en) | Water-soluble filter for use in assays |